ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Remission Rates Double At Phase II
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.